Casi Pharmaceuticals, Inc. (NASDAQ:CASI)

CAPS Rating: No stars

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.


Player Avatar hlacheen (99.20) Submitted: 12/21/2006 9:39:39 PM : Underperform Start Price: $18.59 CASI Score: +145.89

Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m

Featured Broker Partners